Intradigm Corporation
Intradigm is a private biotechnology company dedicated to the development of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology.
At present, Intradigm is working to build a high-value internal pipeline of RNAi oncology therapeutics, and is actively advancing its lead drug candidate, ICS-283, for a variety of cancer indications. The company is also establishing collaborative relationships with pharmaceutical and biotechnology companies through which Intradigm's advanced RNAi delivery technology may be applied to a broad range of therapeutic targets.
3350 W Bayshore Rd, Suite 100
Palo Alto, CA 94303 USA
(650) 855 9696
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||